Ferric oxyhydroxide
Ferric Oxyhydroxide, Ferrlecit, Infed, Velphoro, Venofer (ferric oxyhydroxide) is a small molecule pharmaceutical. Ferric oxyhydroxide was first approved as Infed on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Velphoro
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
33 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anemia | D000740 | EFO_0004272 | D64.9 | — | 3 | 5 | 9 | 2 | 18 |
| Iron-deficiency anemia | D018798 | — | D50 | 1 | 1 | 3 | 8 | 1 | 13 |
| Iron deficiencies | D000090463 | — | E61.1 | 1 | 1 | 3 | 8 | 1 | 13 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | 1 | — | 4 | 1 | 7 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | 4 | 1 | 6 |
| Hyperphosphatemia | D054559 | — | — | — | 1 | 3 | 1 | 2 | 6 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | 1 | 3 | — | 4 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | 2 | — | 3 |
| Deficiency diseases | D003677 | EFO_1001067 | E63 | — | 1 | 1 | 1 | — | 2 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | 2 | — | 2 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | — | — | 1 | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | — | 1 | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | — | — | 1 | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | — | — | 1 | — | — | 1 |
| Precancerous conditions | D011230 | — | — | — | — | 1 | — | — | 1 |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | — | — | 1 | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | — | — | 1 | — | — | 1 |
| Plasmacytoma | D010954 | — | C90.3 | — | — | 1 | — | — | 1 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | 1 | — | — | 1 |
| Intestinal diseases | D007410 | — | K63.9 | — | — | 1 | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ferric oxyhydroxide |
| INN | _ |
| Description | Sucroferric oxyhydroxide, sold under the brand name Velphoro, is a non-calcium, iron-based phosphate binder used for the control of serum phosphorus levels in adults with chronic kidney disease (CKD) on haemodialysis (HD) or peritoneal dialysis (PD). It is used in form of chewable tablets.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 12134-57-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3039566 |
| ChEBI ID | — |
| PubChem CID | 91502 |
| DrugBank | — |
| UNII ID | 87PZU03K0K (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 701 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
9,912 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use